Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + loratadine + pseudoephedrine
- Development stage
- Unknown
- Lead developer
- Changzhou Yabang
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a fixed-dose small molecule combination product developed by Jiangsu Yabang Pharmaceutical Group for the symptomatic treatment of the common cold and influenza. It contains three active ingredients: acetaminophen, loratadine, and pseudoephedrine. Acetaminophen serves as an analgesic and antipyretic to reduce fever and alleviate pain. Loratadine is a second-generation, non-sedating antihistamine that targets the H1 receptor to relieve symptoms such as sneezing and runny nose. Pseudoephedrine acts as a sympathomimetic decongestant to reduce nasal congestion by promoting vasoconstriction in the nasal mucosa. The product is formulated as an extended-release tablet to provide sustained relief from multi-symptom respiratory infections and is currently approved for marketing in China.
- Brand names
- 氨酚氯雷伪麻缓释片
- Other names
- Acetaminophen + Loratadine + Pseudoephedrine Extended-Release Tablets对乙酰氨基酚氯雷他定伪麻黄碱缓释片对乙酰氨基酚氯雷他定伪麻黄碱
02
Targets
HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)ADRA1A (α1A)ADRB1 (β1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on acetaminophen + loratadine + pseudoephedrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + loratadine + pseudoephedrine.